Alleged irregularities in raising funds through FCCBs are likely to be probed by the watchdog, said sources.
Sebi may reopen insider trading case against Sun Pharma
More from Industry NewsMore posts in Industry News »
- India tops the chart for approved biosimilars and clinical trials surpassing USA and Europe: 10th Annual Pharma IPR India Conference
- India initiates antidumping probe on certain type of steel from Brazil, China, Germany
- BDR Pharma receives DGCI nod for its generic drug BIAPENEM
- AstraZeneca invests in Imperial’s self-amplifying RNA technology with eye on future drugs